Acute and chronic effects of continuous positive airway pressure therapy on left ventricular systolic and diastolic function in patients with obstructive sleep apnea and congestive heart failure.
BACKGROUND
Obstructive sleep apnea (OSA) may contribute to the pathogenesis of congestive heart failure (CHF). Nocturnal continuous positive airway pressure (CPAP) therapy can alleviate OSA and may have a role in the treatment of CHF patients.


OBJECTIVE
To investigate the acute and chronic effects of CPAP therapy on left ventricular systolic function, diastolic function and filling pressures in CHF patients with OSA.


METHODS
Twelve patients with stable CHF (New York Heart Association II or III, radionuclide ejection fraction lower than 40%) underwent overnight polysomnography to detect OSA. In patients with OSA (n=7), echocardiography was performed at baseline (awake, before and during acute CPAP administration) and after 6.9+/-3.3 weeks of nocturnal CPAP therapy. Patients without OSA (n=5) did not receive CPAP therapy, but underwent a baseline and follow-up echocardiogram.


RESULTS
In CHF patients with OSA, acute CPAP administration resulted in a decrease in stroke volume (44+/-15 mL versus 50+/-14 mL, P=0.002) and left ventricular ejection fraction ([LVEF] 34.8+/-5.0% versus 38.4+/-3.3%, P=0.006) compared with baseline, but no change in diastolic function or filling pressures (peak early diastolic mitral annular velocity [Ea]: 6.0+/-1.6 cm/s versus 6.3+/-1.6 cm/s, P not significant; peak early filling velocity to peak late filling velocity [E/A] ratio: 1.05+/-0.74 versus 1.00+/-0.67, P not significant; E/Ea ratio: 10.9+/-4.1 versus 11.3+/-4.1, P not significant). In contrast, chronic CPAP therapy resulted in a trend to an increase in stroke volume (59+/-19 mL versus 50+/-14 mL, P=0.07) and a significant increase in LVEF (43.4+/-4.8% versus 38.4+/-3.3%, P=0.01) compared with baseline, but no change in diastolic function or filling pressures (Ea: 6.2+/-1.2 cm/s versus 6.3+/-1.6 cm/s, P not significant; E/A ratio: 1.13+/-0.61 versus 1.00+/-0.67, P not significant; E/Ea ratio: 12.1+/-2.7 versus 11.3+/-4.1, P not significant). There was no change in left ventricular systolic function, diastolic function or filling pressures at follow-up in CHF patients without OSA.


CONCLUSIONS
Acute CPAP administration decreased stroke volume and LVEF in stable CHF patients with OSA. In contrast, chronic CPAP therapy for seven weeks improved left ventricular systolic function, but did not affect diastolic function or filling pressures. The potential clinical implications of the discrepant effects of CPAP therapy on left ventricular systolic and diastolic function in CHF patients with OSA warrant further study.
Johnson
Chris B
CB
Department of Medicine, University of Ottawa, Ottawa, Canada.
Beanlands
Rob S
RS
Yoshinaga
Keiichiro
K
Haddad
Haissam
H
Leech
Judith
J
de Kemp
Rob
R
Burwash
Ian G
IG
D045422:Continuous Positive Airway Pressure; D003971:Diastole / Q000502:physiology*; D015150:Echocardiography, Doppler; D005260:Female; D006333:Heart Failure / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D020181:Sleep Apnea, Obstructive / Q000503:physiopathology / Q000628:therapy*; D013318:Stroke Volume / Q000502:physiology; D013599:Systole / Q000502:physiology*; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging / Q000503:physiopathology*
Am J Respir Crit Care Med. 2001 Feb;163(2):344-8
11179104
Circulation. 1990 Feb;81(2 Suppl):III78-86
1967559
Circulation. 1998 Nov 24;98(21):2269-75
9826313
J Am Coll Cardiol. 1997 Nov 15;30(6):1527-33
9362412
Am Rev Respir Dis. 1993 Mar;147(3):630-4
8442598
Lancet. 2002 Jul 20;360(9328):237-45
12133673
N Engl J Med. 2003 Mar 27;348(13):1233-41
12660387
Lancet. 2002 Jan 19;359(9302):204-10
11812555
Circulation. 2003 Apr 8;107(13):1822-6
12682029
J Am Soc Echocardiogr. 1989 Sep-Oct;2(5):358-67
2698218
Am J Respir Crit Care Med. 1996 Apr;153(4 Pt 1):1333-8
8616563
J Am Coll Cardiol. 2005 Apr 19;45(8):1223-6
15837253
J Appl Physiol (1985). 1985 Apr;58(4):1189-98
3988674
J Am Coll Cardiol. 1995 Mar 1;25(3):672-9
7860912
Heart. 2003 Nov;89 Suppl 3:iii18-23
14594871
Anesthesiology. 1990 Jun;72(6):966-70
2190501
Circulation. 1998 Sep 15;98(11):1071-7
9736593
Am J Cardiol. 2003 Mar 15;91(6):780-4
12633827
Am J Respir Crit Care Med. 1994 Jun;149(6):1614-8
8004320
Circulation. 2000 Jul 4;102(1):61-6
10880416
J Am Coll Cardiol. 1997 Jul;30(1):8-18
9207615
Lancet. 1999 Jun 19;353(9170):2100-5
10382693
Circulation. 1998 Jun 2;97(21):2154-9
9626176
Am Heart J. 1996 Apr;131(4):766-71
8721653
J Am Coll Cardiol. 2005 Jun 21;45(12):2008-11
15963401
Am J Respir Crit Care Med. 1995 Aug;152(2):473-9
7633695
Chest. 2003 Aug;124(2):594-601
12907548
J Appl Physiol Respir Environ Exerc Physiol. 1983 Apr;54(4):950-5
6853301
Am Rev Respir Dis. 1992 Feb;145(2 Pt 1):377-82
1736745
Lancet. 1991 Dec 14;338(8781):1480-4
1683918
J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63
16376782
Am Rev Respir Dis. 1989 Nov;140(5):1257-64
2573303
Circulation. 1994 Dec;90(6):2772-9
7994820
J Am Soc Echocardiogr. 1997 Apr;10(3):246-70
9109691
Am J Respir Crit Care Med. 2004 Feb 1;169(3):361-6
14597482
Circ Res. 1986 Sep;59(3):270-82
2429780
J Am Coll Cardiol. 1997 Mar 1;29(3):604-12
9060900
J Am Soc Echocardiogr. 2002 Feb;15(2):167-84
11836492
Circulation. 2005 Jul 19;112(3):375-83
16009798
Circulation. 2003 Apr 1;107(12):1671-8
12668504
Eur Respir J. 1995 Mar;8(3):430-5
7789489
Am J Respir Crit Care Med. 1995 Jan;151(1):92-7
7812579
Circulation. 1999 Dec 7;100(23):2332-5
10587337
Am J Respir Crit Care Med. 1994 Jan;149(1):149-54
8111574
J Am Coll Cardiol. 1994 Jul;24(1):132-9
8006256
Circulation. 2000 Oct 10;102(15):1788-94
11023933
Circulation. 2002 Jan 29;105(4):539-42
11815441
Am J Respir Crit Care Med. 1999 Oct;160(4):1101-6
10508793
Circulation. 2001 May 15;103(19):2336-8
11352880
J Appl Physiol Respir Environ Exerc Physiol. 1984 Mar;56(3):619-27
6368501
Circulation. 2004 May 25;109(20):2432-9
15123522
N Engl J Med. 1981 Feb 12;304(7):387-92
7005679
Lancet. 1994 Mar 5;343(8897):572-5
7906330
J Clin Invest. 1995 Oct;96(4):1897-904
7560081